Related Experiment Video
Updated: May 9, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
From conventional therapy to novel nano-based approaches. A focus on prostate cancer
Lorenzo Chiaverini1, Giarita Ferraro2, Riccardo Di Leo1,3
1Department of Pharmacy, University of Pisa, Pisa, Italy.
Abstract:
The currently available clinical anticancer approaches pertaining to the treatment of prostate cancer are summarized here. After providing an overview of the main features of this highly impactful global disease, the currently available clinical treatments are briefly reviewed. Then, alternative and innovative nano-based therapeutic options that have been proposed or are currently being explored to significantly improve prostate cancer management (i.e. anti-prostate cancer polymeric nanoparticles loaded with drugs to promote their release and biological activity, including non-targeted and functionalized PLGA-PEG NPs and AuNPs), are introduced. Furthermore, the problem of gathering insights into the mechanistic aspects related to the fate of the nanoformulation in complex matrices, such as blood plasma, is addressed.
Insights
This review summarizes current prostate cancer treatments and explores innovative nanoparticle-based therapies, like PLGA-PEG NPs and AuNPs, to enhance drug delivery and efficacy for better cancer management.
Area of Science:
- Oncology
- Nanomedicine
- Materials Science
Background:
- Prostate cancer is a significant global health concern with substantial impact.
- Current clinical treatments for prostate cancer are established but have limitations.
Purpose of the Study:
- To review existing prostate cancer therapies.
- To introduce novel nano-based therapeutic strategies for improved prostate cancer management.
- To address challenges in understanding nanoparticle behavior in biological systems.
Main Methods:
- Literature review of current clinical anticancer approaches for prostate cancer.
- Exploration of emerging nano-based therapeutic options, including polymeric nanoparticles (PLGA-PEG NPs) and gold nanoparticles (AuNPs).
- Discussion of mechanistic aspects concerning nanoformulation fate in complex biological matrices like blood plasma.
Main Results:
- Summary of current clinical treatments for prostate cancer.
- Introduction of drug-loaded polymeric nanoparticles (PLGA-PEG NPs) and gold nanoparticles (AuNPs) as innovative therapeutic agents.
- Highlighting the need for further research into the in vivo behavior of nanotherapeutics.
Conclusions:
- Nanoparticle-based therapies offer promising avenues for enhancing prostate cancer treatment efficacy.
- Further investigation into the pharmacokinetics and biodistribution of nanomedicines is crucial.
- Innovative nanocarriers show potential to overcome limitations of conventional prostate cancer therapies.
More Related Videos
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
08:36Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
Published on: October 24, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...